Development of a Gastric Cancer Screening Intervention for H. Pylori Carriers Based on the Health Belief Model (HBM-GCS)
Development of a Gastric Cancer Screening Intervention Program for Helicobacter Pylori Carriers Based on the Health Belief Model
Gastric cancer (GC) remains a major global public health challenge. It often causes no obvious symptoms in the early stage, so most patients are diagnosed at an advanced stage. This highlights the importance of gastric cancer screening among high-risk populations to achieve early detection and improve survival outcomes. People infected with Helicobacter pylori (Hp) are at high risk of gastric cancer. Hp is one of the most common bacterial infections worldwide. It initiates carcinogenesis by triggering chronic atrophic gastritis and intestinal metaplasia, known as the Correa cascade. However, the acceptance of gastric cancer screening among Hp-infected individuals is still unsatisfactory. To our knowledge, there are few theory-based interventions designed to help Hp-infected people make decisions about gastric cancer screening and increase screening uptake. Therefore, based on our previous systematic review, this study aims to develop a health promotion program to improve gastric cancer screening participation among Hp-infected individuals in mainland China. Participants in the intervention group will receive a comprehensive health promotion program, including a 30-minute health education session. They will receive a 15-minute telephone follow-up with gastric cancer screening information in week 2, and additional 10-minute telephone follow-ups at weeks 2, 4, and 6 to help participants identify and overcome barriers to gastric cancer screening. Participants in the control group will receive routine care. Data on gastric cancer screening participation will be collected at the end of the intervention. Findings from this study will be valuable for gastric cancer prevention among people with Hp infection.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Participants in the intervention group will receive the following multi-session health promotion intervention. The details are as follows.
Screening benefit construction (30 min). In the first week, education will be delivered through face-to-face for the following information:
(1) Hp infection and increased gastric cancer risk; (2) gastric cancer screening recommendations regarding eligibility, available screening tests, and recommended screening intervals; (3) pros/advantages of undergoing gastric cancer screening; (4) cons/disadvantages or uncertainties of undergoing gastric cancer screening; (5) implications of positive screening results; and (6) health costs and service information. The educational material will be presented in a self-made manual, which will be explained and distributed to each participant.
Screening barrier navigation (15 min). It will be conducted in the second week by telephone. The nurse counsellor will help participants resolve individual barriers related to gastric cancer screening. The tailored content includes:
(1) Q&A about gastroscopy screening; (2) gastroscopy appointment procedure; (3) hospital and transportation information; (4) medical insurance consultation; (5) precautions for the examination.
Screening self-efficacy reinforcement (10 min each). At the fourth and sixth weeks, the nurse counsellor will work with participants through a telephone-based way (with WeChat as an auxiliary tool) to strengthen confidence in completing gastric cancer screening, in which participants will: (1) track the progress of screening arrangements; (2) receive home health guidance while waiting for the screening examination.
Participants in the control group will receive routine health care for Hp infection without this theory-based gastric cancer screening promotion program.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Mengyao Gao, MN
- Número de telefone: (86)15870682367
- E-mail: 15870682367@163.com
Estude backup de contato
- Nome: Caixia Li, PhD
- Número de telefone: (86) 19867712062
- E-mail: licx23@mail.sysu.edu.cn
Locais de estudo
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518000
- The University of Hong Kong-Shenzhen Hospital
-
Contato:
- Mengyao Gao, MN
- Número de telefone: (86)15870682367
- E-mail: 15870682367@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Aged between 45 and 74 years.
- Diagnosed with *Helicobacter pylori* infection confirmed by urea breath test (UBT), serological antibody test, or stool antigen test.
- Have adequate communication, reading, and comprehension ability.
- Provide informed consent, voluntarily participate in the study, and cooperate with all study procedures.
Exclusion Criteria:
-
1. Previously diagnosed with gastric cancer or other advanced malignant tumors. 2. Cognitive impairment, severe hepatic or renal insufficiency, psychiatric disorders, or severe physical illness that prevents cooperation with the interview.
3. Pregnant or breastfeeding women.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Triagem
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Experimental: Health Belief Model-based intervention group
Provide education, tailored information, barrier counseling, and decision support regarding gastric cancer screening for Helicobacter pylori-infected individuals. |
Provide health education, tailored information, barrier counseling and follow-up regarding gastric cancer screening for Helicobacter pylori-infected individuals. |
|
Outro: Control group
Usual care provided by the hospital, including one-page written education material on gastroscopy. |
Usual care provided by the hospital, including one-page written education material on gastroscopy. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Gastric cancer screening intention
Prazo: Immediately and 6 weeks after intervention
|
Participants' behavioral tendency and psychological readiness to actively seek and undergo gastroscopy within the next 5 years. |
Immediately and 6 weeks after intervention
|
|
Gastroscopy completion rate
Prazo: 6 weeks after intervention
|
An objective outcome is defined as the number of participants who complete gastroscopy after intervention. The gastroscopy completion rates among Helicobacter pylori-infected participants in the two groups will be compared, serving as the key quantitative indicator to evaluate whether the intervention improves actual screening behavior. |
6 weeks after intervention
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Gastric cancer screening knowledge score
Prazo: Immediately and 6 weeks after intervention
|
Assessed with knowledge items from Huang et al. (2022). The scale measures participants' knowledge of gastric cancer risk factors and warning symptoms, consisting of 24 items on risk factors and 14 items on warning symptoms. |
Immediately and 6 weeks after intervention
|
|
Total score of the Health Belief Model (HBM) questionnaire for gastric cancer screening
Prazo: Immediately and 6 weeks after intervention
|
This subscale was developed based on the five-dimensional HBM framework proposed by Becker (1974), including perceived susceptibility to gastric cancer (3 items), perceived severity (3 items), perceived benefits of gastric cancer screening (2 items), perceived barriers to screening (5 items), and cues to action (3 items). The total score of the five dimensions is calculated. |
Immediately and 6 weeks after intervention
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Mengyao Gao, MN, Kiang Wu Nursing College of Macau(KWNC)
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- Gastric Cancer Screening
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .